Hello everyone, and welcome to the Agilon Health Q3 2023 earnings conference call. My name is Carla, and I will be your operator for today's call. Today's call will include a Q&A session. If you wish to register a question, please press star followed by one on your telephone keypad. If you wish to revoke your question at any point, please press star followed by two. I will now hand you over to your host, Matthew Gillmor, Vice President of Investor Relations. Matthew, please go ahead. Thanks, operator. Good afternoon, and welcome to the call. With me is our CEO, Steve Sell, and our CFO, Tim Bensley. Before we begin, we'd like to remind you that our remarks and responses to questions may include forward-looking statements. Actual results may differ materially from those stated or implied by forward-looking statements due to risks and uncertainties associated with our business. These risks and uncertainties are discussed in our SEC filings. Please note that we assume no obligation to update any forward-looking statements. Additionally, certain financial measures we will discuss in this call are non-GAAP measures. We believe that providing these measures helps investors gain a better and more complete understanding of our financial results and is consistent with how management views our financial results. A reconciliation of these non-GAAP financial measures to the most comparable GAAP measure is available in the earnings press release and Form 8-K. Following prepared remarks from Steve and Tim, we'll conduct a Q&A session. During the Q&A session, we'd ask everyone to please limit themselves to one question, so we can get through as many questions as possible. With that, I'll turn things over to Steve. Thanks, Matt. Good evening, and thank you for joining us. Momentum across our business remains strong, and we are making rapid progress against our vision to transform healthcare in 100+ communities by empowering primary care doctors. As an indicator of our success, this year, we are on track to reinvest more than $250 million into local primary care based on the high quality, cost-effective care being delivered by our partners. These results are enabling our partner groups to expand access to preventative services, improve quality outcomes, and drive value for the communities they serve. I want to thank my Agilon colleagues and our partners for their trust in each other and their belief and support in a network that is shaping a better healthcare system for our country. Before discussing our performance for the quarter, I wanted to take a few moments to highlight our decision to sell our Hawaii business. As we have discussed with you, Hawaii operates very differently compared to our core partner markets in the continental U.S. In our core partner markets, we leverage a common operating structure. This operating structure is centered around a long-term joint venture with a scaled physician group and non-delegated multi-payer relationships with health plans and CMS. The key differences in Hawaii's operations, namely, the lack of a joint venture partnership with a large physician group, a much smaller senior patient physician panel size, and Hawaii's delegated MSO infrastructure, made our Hawaii business increasingly less strategic to Agilon and created a drag on our financial results. We are pleased to transition MDX Hawaii to a new owner that is better positioned to invest into the business and optimize its delegated infrastructure, which should benefit patients and the community at large. The sale of Hawaii will enhance our ability to focus even more specifically on our partner markets. At a point in time when we are driving increasing success across a PCP's entire senior panel. This quarter and going forward, you will hear us consistently highlight the power and importance of our integrated senior business across Medicare Advantage and the traditional Medicare populations. Our ability to generate successful outcomes for patients, PCPs, and the system in a multi-payer, full risk model is increasingly unique. Our focus on this opportunity will pay dividends in the years to come. Turning now to the quarter, partner market performance was again extremely strong across both MA and ACO REACH. All of our key financial metrics were generally in line or above our guidance ranges, especially on an underlying basis. Our results continued to demonstrate the unique power of our model to inflect profitability while driving significant growth. During the quarter, our total membership on the platform increased 43% to 508,000 members, and revenues increased 75% to $1.2 billion. This was above our guidance and was supported by the successful onboarding of new PCPs and faster pull-through of members, particularly in new markets. Adjusted for the sale of MDX Hawaii, our partner market growth was even stronger, with total membership up 49% and revenue up 85%. Even with our faster membership growth, adjusted EBITDA continues to inflect higher, increasing more than $20 million year-over-year to a loss of $6 million for the quarter. This was in line with our outlook and supported by strong medical margin gains in our partner markets across MA and REACH. Adjusted for Hawaii, our partner market, EBITDA, was +$6 million for the quarter, well above our outlook, and it was even stronger on an underlying basis as our results included some net negative development from 2022. Our combined medical margin across MA partner markets and REACH was strong in the quarter, with MA generating $111 million and REACH generating $55 million.... These results demonstrate the power of a PCP focusing on the most complex patients across their entire senior panel, with differentiated information and care team resources. As an example, our year two-plus partner markets in MA and REACH both generated over $130 per member per month in medical margins year to date. Think about the value delivery to our PCP partners and the health system when we generate this magnitude of savings across an average panel size of 400-500 senior patients. From a guidance perspective, we have raised our membership, revenue, and adjusted EBITDA outlook for 2023. This was supported by the growth and margin progression in our MA partner markets, including REACH, and the sale of MDX Hawaii. We also plan to maintain a more conservative reserving approach as we exit 2023, and this is intentionally reflected in our medical margin outlook for MA and will support our future performance in 2024. Our ability to execute against our adjusted EBITDA targets during 2023 and enhance our visibility to 2024 continues to reflect the strength and durability of our model. As I have discussed with you previously, the key differences in our model are driving differentiated clinical and financial performance. Unlike the traditional Fee-for-Service system, which predominates across healthcare, all patients in our model have a fully aligned or attributed relationship with their primary care doctor. Through Agilon's platform, our PCP partners have the data and resources to proactively impact patient care. This translates into specific differences in the way healthcare is utilized and managed, and this shows up in our business in very tangible ways. For example, we continue to have outstanding results in the standardized star ratings measures. For 2024 stars, the percentage of our membership in 4+ star plans will increase modestly to approximately 84%. However, as most of you know, plan-level star ratings also include the performance of non-Agilon providers. For our year two-plus partners, Agilon's specific performance is 4.3 stars and increased nicely year-over-year. This was despite more stringent cut points and relatively flat star ratings industry-wide. We continue to excel in areas like preventative cancer screenings, diabetes control, and medication adherence. Our quality results will drive meaningful value to our patients and the healthcare system in the years ahead. Because of our high member retention, Agilon and our physician partners will share in this value over the long term. Additionally, our ability to drive differentiated cost performance was clearly evident in the recently released ACO REACH results for 2022. This data allows Agilon to compare our performance against the unmanaged fee-for-service system, as well as other value-based care models. During 2022, our REACH ACOs drove nearly 10% savings relative to the Medicare benchmark. This was more than 2.5 times better than the program average, and our results included more than 90,000 beneficiaries in diverse markets. Agilon also returned nearly $30 million in guaranteed savings to the Medicare Trust Fund last year. As you can see from our REACH results this quarter, our differentiated cost performance has carried into 2023. Looking forward, we believe our leadership position as the platform and network moving physicians to full risk has grown considerably. This is a function of the magnitude of savings we are generating across the entire senior panel of a primary care doctor. Our timing is also important, as primary care physicians and the broader system increasingly need a scalable solution for multi-payer full risk. This dynamic is driving the ongoing inflection we are seeing from a demand perspective among both physician groups and health systems. For the Class of 2024 new partners, we now expect 25,000 new ACO REACH members, and we are increasing our expectation from 100,000 to 110,000 new MA members. At this point in the year, we are nearly complete with our payer contracting cycle, which gives us better visibility into the membership pull-through. We also now have a clear line of sight to a very strong Class of 2025, with multiple new partners signed, including independent groups and health systems. Implementation for this class has already begun, which should bode well for future performance. Before turning the call over to Tim, I wanted to offer a few comments on 2024. We remain highly confident in the trajectory of our adjusted EBITDA inflection and expect to share an initial view in early January. As we have discussed previously, we operate in a very forward-looking model, and our visibility into the key drivers for next year's performance are quite high. First, we have a large and growing Class of 2024 new partners with an attractive margin profile that should be meaningfully accretive to adjusted EBITDA. This is a function of the longer implementation cycle for this class and targeted investments we have made around technology and centralizing key processes..... Next, the combined strength of our 2023 run rate margins across our integrated senior business will have key positive implications for 2024. First, our REACH performance will carry forward, driven by our ability to maintain the cost differential compared to the benchmark. Second, the reserve actions we have taken in Medicare Advantage should reduce the risk of negative claims development next year. Finally, we remain very confident in our ability to manage the new risk adjustment model starting in 2024. The impact to Agilon from the V28 model change is relatively modest, and given the limited maturity of our partner markets and senior membership, our ability to mitigate this impact is very high. With that, let me turn things over to Tim. Thanks, Steve, and good evening, everyone. I'll now review highlights from our Q3 results and our updated outlook for 2023. starting with our membership for the Q3, total members live on the Agilon platform increased to approximately 508,000, including both Medicare Advantage and ACO REACH. Our consolidated Medicare Advantage membership increased 58% to 420,000, driven by the addition of new partner geographies and 9% growth with our same geographies. Adjusted for Hawaii, MA membership and our core partner markets grew 69% to 384,000, and our same geography growth was 12%. Reported revenues increased 75% on a year-over-year basis to $1.2 billion during the Q3. Year-to-date, revenues increased 73% to $3.5 billion. Revenue growth was primarily driven by membership gains in new and existing geographies. On a per member, per month basis, or PMPM, Q3 revenue increased 11%. This was primarily driven by benchmark updates and membership mix, including higher benchmarks in several new markets. Adjusted for Hawaii, revenues increased 85% to $1.1 billion, and revenue PMPM increased 10% during the Q3. For our MA business, medical margin on a reported basis increased 42% year-over-year to $108 million during the Q3. Year-to-date, medical margin increased 67% to $408 million. While this was below our outlook for the quarter, the difference was primarily driven by performance in Hawaii. Adjusted for Hawaii, medical margins increased 46% year-over-year to $111 million for the Q3 and was in line with our expectation, even with approximately $6 million of net negative development. On a per member, per month basis, medical margins across our core partner markets increased by 4% year-to-date to $119, driven by the maturation of markets and member cohorts. For our year 2+ partner markets, Medical Margin PMPM increased 17% to $134 on a year-to-date basis. MA medical margins for the quarter included a net $8 million in negative development, including $9 million in prior year claims, offset by $1 million in prior year revenue. $2 million of the net development was attributed to Hawaii, and the remaining $6 million was attributed to our core partner markets. The negative claims development this quarter was almost entirely isolated to system issues with a single payer related to supplemental benefit costs. As we discussed last quarter, we are making focused investments to improve our visibility into data gaps with payers. Excluding the year-to-date development, MA medical margins would have been approximately $125 PMPM in our partner markets and $143 PMPM in our year two plus partner markets. We think this is an important metric as it better reflects the year-to-date run rate performance of our MA business in light of the sale of MDX Hawaii and the actions we have taken to minimize the risk of negative development in 2024. For our ACO REACH business, we continue to be very encouraged with the performance, which again outperformed our guidance this quarter. REACH generated $55 million of medical margin in the quarter and $117 million year to date, which is a twofold increase from last year. Additionally, on a per member, per month basis, REACH profitability this year is roughly comparable to the year two plus MA partner markets. This level of performance is encouraging and underscores the power of our multi-payer full risk platform. While REACH is not consolidated in our financial results, we do think it is relevant to think about our medical margin performance on a combined basis across our MA partner markets and REACH. This is because our combined MA and REACH performance is what drives our key profitability metric, adjusted EBITDA. For 2023, our combined medical margins for MA partners and REACH are consistent with our original guidance expectations. As Steve mentioned, this sets a strong foundation for performance in 2024. Our adjusted EBITDA on a reported basis was -$6 million in the quarter, compared to -$26 million last year. On a year-to-date basis, adjusted EBITDA was +$28 million, compared to -$20 million last year. As a reminder, adjusted EBITDA includes geography entry costs primarily associated with new partners that will generate revenue in 2024. The year-over-year gain in adjusted EBITDA reflects the increase to our medical margins across both MA and REACH, as well as platform support leverage, partially offset by performance in Hawaii and the net negative development. Excluding Hawaii, our adjusted EBITDA would have been +$6 million for the quarter and $42 million on a year-to-date basis. From a utilization standpoint, composite utilization across MA and REACH was generally in line with expectations. For MA, we did observe an increase in utilization during May and early June, which resulted in some in-period development that we recognized during the Q3. This was contemplated in our guidance, and trends moderated back towards normalized levels during the Q3. For REACH, utilization during the H1 of 2023 developed favorably relative to our expectation. As a reminder, our results in REACH better reflect our real-time performance against the unmanaged fee-for-service system because of how the benchmark mechanics work. Turning now to our outlook for full year 2023. Please note that our updated guidance excludes MDX Hawaii for the full year. We have raised and narrowed our adjusted EBITDA outlook to a range of $6 million-$18 million, from a prior range of $0-$23 million. We have also updated our membership and revenue outlook, which are both higher on an underlying basis, excluding MDX Hawaii. From a medical margin perspective, our revised outlook is $455 million-$470 million, and is approximately $50 million lower than our prior range. This reflects two factors. First, the removal of Hawaii represents about $20 million of this change. Second, one of our primary goals is to exit 2023 with appropriately conservative reserving posture in MA. In light of this, we continue to proactively refine our model to account for utilization trends, as well as any potential blind spots with health plans. We have assumed utilization will not moderate any further from recent levels, which accounts for $30 million of the change to our MA medical margins. We think this is a prudent approach and is informed by our decision to maintain a more conservative reserving posture. We are pleased to make these decisions, which provide a strong foundation for future performance, while still modestly raising our adjusted EBITDA guidance. Full details on our Q4 and full year guidance can be found in the earnings press, press release. With that, let me turn the call back to Steve for some brief closing comments. Yeah. Thanks, Tim. Before opening up the lines, I wanna emphasize three key points. First, the sale of our Hawaii business enhances our ability to focus even more specifically on our differentiated core partner business, and positions us for continued success in 2024 and beyond. Second, our leadership position as the platform and network, moving physicians to full risk, has grown considerably, and you can see it in the clinical and financial results we are driving, and in the accelerating demand from physicians in independent groups and health systems. And third, with access to better data, resources, and incentives, our primary care doctors are actively managing the way healthcare is utilized across their entire senior panel, which is yielding meaningfully better outcomes for doctors, patients, and Agilon. With that, we are now ready to take your questions. Thank you. If you'd like to ask a question today, you may do so by pressing star, followed by one on your telephone keypad. When preparing for your question, please ensure your device is unmuted locally. If you wish to revoke your question, please press star followed by two. We will now take our first question, which comes from Lisa Gill from JPMorgan. Lisa, your line is now open. Please go ahead. Thanks very much, and congratulations on the sale of Hawaii. Although I was looking forward to doing a site tour, Steve, so I guess that's off the table. Just wanted to follow up on the medical cost side. So, Tim, you talked about system issue with a single payer, data gaps with that payer. If I remember last quarter, you also talked about increasing reserves to try to account for some of this going into the back half of the year, and then we saw the prior period development here in this quarter. Can you just talk about where you are on that data gap, the systems issue? Do you feel like that's fully behind you? And then secondly, when talking about utilization, you said in line, you saw a little bit of a bump in May and June. What we saw with some of the Medicare Advantage players in the most recent quarter is that, you know, in the quarter, they actually saw higher costs than they were projecting, even beyond May and June. And one of the largest players talked about, you know, some COVID hospitalizations that they saw towards the end of the September quarter. So just wanna really understand, you know, what you saw, what your expectations were, and if you have anything on the COVID side, or if you've seen anything on the COVID side. So, Lisa, I'll start and Tim can chime in. I mean, I think, you know, I'll start with the raised EBITDA guide on the year because of the strong overall performance across MA and REACH, across nearly 500,000 senior patients, and that really sets a strong foundation for 2024. From a utilization perspective, composite utilization was in line with our overall expectations. As Tim kinda outlined, we did see a step up in Q2 utilization in MA and REACH. The MA was within our guide. REACH actually developed favorably relative to sort of what our expectation was around that intraperiod. In Q3, we've seen a deceleration, and our guide makes an assumption on utilization that it'll be flat through the end of the year. And that's reflected in the reserve posture that Tim talked about in terms of an extra $30 million. But Tim, you wanna talk about? Yes, Lisa, just a couple of things specifically to your question. First of all, on the prior period development, I think we have made a lot of progress this year in partnering with, with the payers out there to try to close some of these gaps. You know, essentially, some of these information issues are caused by just the complexity of our model, and that's also, you know, it's also a feature of the model, right? We've got, you know, over 30 payers, over 100 payer contract combinations in our markets. But having said that, I think we made good progress. The issue in this quarter was a very specific issue with just one payer. You know, hopefully, that was a lingering issue that we've now, you know, figured out where the gap was and should be okay with that going forward. In terms of the utilization trend, you know, remember last quarter when we talked about this, we said, "Hey, we haven't seen the spike up yet." We didn't have enough information for May or June to really see what some of the payers were referring to. We did wanna make sure that, you know, we had covered the possibility that there would be some higher utilization in our guidance going forward. As it turned out, as we just reported, we did see some increased utilization in May, although it was, you know, greatly started to moderate in June, and as we've seen so far, started to, you know, continue to moderate in early Q3 as well. I'm not completely surprised by that compared to some of the comments that I've made from some of the big payers. I mean, I think our model, and even some of them have said, should be performing better than the average out there. So, you know, the fact that we saw a spike up and some moderation down is probably just a factor also of the strength of our model. On COVID, specifically, we're actually seeing. Yep, if you go back to last year, which is, you know, might wanna think about that as the first really sort of post big COVID year, we did actually see some seasonality with COVID starting to spike up last year in kind of the August and September time frame in terms of utilization. We did see some of that again this year, although actually lower spike up in COVID this year than even we saw last year. And the overall magnitude of, you know, hospitalization from COVID in terms of a spike up versus a baseline is not really, you know, material and not causing any material change in our medical margin performance or our medical margin outlook. Great. Thank you. Thanks, Lisa. Thank you, Lisa. We will now take our next question from Justin Lake from Wolfe Research. Justin, your line is now open. Please go ahead. Thanks, appreciate the time. Wanted to start off, I've got a couple of questions, but wanted to start off on the REACH performance. So you said it was $55 million of medical margin, so give or take half your medical margin in the quarter, what were you expecting it to be in the original guide? Yeah, Justin, just real quick, before, you know, we can obviously talk a lot about the performance of REACH, which was really positive, continued to be really positive in the quarter as it had kind of a year to date so far. But the $55 million of medical margin that we talked about for REACH is not part of our consolidated results. So the $108 million of medical margin that we reported, which does include Hawaii, in addition to that, if you look at the footnotes showing the unconsolidated, ACO REACH entities, we had $55 million there, and about $18 million of EBITDA flow through from that. That's a good point. Yep. I apologize. That's a very- And Justin, if I can just- That's absolutely correct. All right. Yeah, if I can just add to that, Justin, I mean, I think we're driving really strong medical margin performance across the entire physician panel, across both REACH and MA. And so the $55 million that Tim talked about is driven by beating that national benchmark by more than 300 basis points. You know, in my remarks, I talked about the 2022 results. You're seeing that in 2023. But the same things that are driving success in REACH are driving success in MA. And our partner market medical margins came in at $111 million in MA, which is sort of in our guide. And when you adjust for that PPD, it's actually at the high end of our guide. I think it's just a function of this model that we've got around high touch and our ability to drive better access, cost, and quality outcomes. So that, that's what I'd highlight. Yeah, I mean, the ACO REACH population has been, you know, more traditionally an unmanaged population, so, you know, there is a big opportunity for us there. We're tended to be, even as we move through this year, we have very good current data from CMS on our, on our members, and we tended to be a little bit conservative. So we actually saw, you know, even positive development as we moved into Q3. We had guided about a $12 million EBITDA flow-through for ACO REACH. We ended up, you know, with some positive development flowing through from the previous quarter, $18 million. Overall, you know, so far during the year, you know, the way you make money in ACO REACH is, the way you perform well on ACO REACH is essentially you just outperform the Medicare fee-for-service reference population on cost performance, and we're outperforming that on a year-to-date basis by over 300 basis points. So, you know, the model really is starting to, you know, prove to be very valuable on the, on the ACO REACH side. And then, Justin, what was your real question? Sorry. Well, the other question I was gonna ask on ACO REACH, and again, I could be, it's been a long couple of days, I might be off again, but my recollection of the Investor Day was that, you know, you guys actually kinda titrated lower your expectations for ACO REACH. I think I was looking at it, and you would expect that, I think in 2026 to be at... Am I recalling the number right, $35 million- That's right ... of profitability? Okay. So, you know, it, it sounded like you, you had kind of, you know, gotten more conservative or, you know, some, you know, thought process there on like, "Hey, let's, you know, let's take that number down a bit." But so, you know, six months later, you're running at that run rate already, looks like. Is that a number that you think we should be, that, you know, we should be looking at differently than, you know, at, from the Investor Day? Are you thinking about that business differently? Yeah, absolutely. I mean, our emphasizing the power across the entire senior panel is hopefully one of the big takeaways that you're going to have. The way the mechanics and the ACO REACH model work is you carry forward your performance, and you need to beat that underlying benchmark, which we would expect we're going to do again next year. And so I think we feel like we're going to have much stronger performance going forward. We've already seen it this year to date, and it's, you know, we have much more valuable and readily available and consistent information, which is giving us high confidence in that. Got it. All right, I'll jump back in the queue. Thanks, guys. Justin, thanks. Thank you, Justin. We will now take our next question from Stephen Baxter from Wells Fargo. Stephen, your line is now open. Please go ahead. Yeah. Hi, thanks. Just wanted to try to clarify the discussion a little bit on the revision to the medical margin guidance. So I think I'm following you, that you're saying, you know, $20 million of the lower $50-$55 million revision on medical margin is related to pulling Hawaii out. So I guess that leaves, you know, call it the $30 million for the continuing partner markets. I'm just trying to understand, you know, kind of the $30 million in the context of the quarter you just had. It does look like including, you know, I guess, wanting to strip out the Hawaii results out of the quarter, it doesn't really look like you were, you know, kind of off your medical margin guidance that you provided for the Q3. Just trying to understand, you know, why, why you'd have $30 million lower medical margin on a core basis if the quarter was, you know, relatively in line X to Y. It kind of implies it's, it's primarily related to the Q4. Just trying to correct my understanding of that, hopefully, if that made sense. Thanks. Sure, Stephen. Thanks for the question. I mean, I, I think a key goal for us was to raise and beat adjusted EBITDA on the year. We were able to do that based on the strong performance of ACO REACH, and, and across MA, to your point, in, in those partner markets, they were very strong. The second goal was to really put ourselves in a position from a reserving standpoint, in which we could significantly mitigate the chance of any negative development into 2024. And so I think that coupled with this utilization outlook, which we think is prudent, that the deceleration we're seeing in Q3 will not necessarily continue, that's what puts that $30 million on top of the $20 million that you take out for Hawaii. So that's really the logic around it. Yeah, I think that's right. I mean, we as we close Q3, if you put the prior period development aside, and you take the Hawaii, which did perform below our expectation for the quarter out of it, our overall medical margin PMPM did perform, you know, well within the range that we had, that we had guided to, so we were very happy with that. On the other hand, that was a combination of higher revenue as we synced up our final, you know, got all the midyears in and synced up our final, or the next round of our wrap estimates for the year, as well as some higher medical expenses that flowed through from that May and early June spike that we saw. So we just looked at the rest of the year and said, "Hey, if we just assume that there's not really any further moderation, and we want to continue to make sure that we minimize the possibility of any prior period development bleeding over into 2024, if that's an additional $30 million of just medical expense versus what we had in our previous guidance." And we were able to do all that, you know, in addition, with the strength of the ACO REACH business, and the other actions that we just identified were, you know, on top of that, in a position to essentially slightly increase our overall adjusted EBITDA guidance for the year. Thank you, Steven. Thanks, Steven. We will now take our next question. Perfect. Thank you. We will now take our next question from Gary Taylor, from Cowen. Gary, your line is now open. Please go ahead. Thanks. I had a couple of questions. The first one, just on Hawaii, why was that, I think I'm talking at the EBITDA line, if I wrote it down correctly. But why was that a $11 million drag, in the Q3, when I think in the H1 it was only a $2.5 million drag? Like, and all those sort of metrics on Hawaii got quite a bit worse in the Q3? Yeah, I mean, generally speaking, as we move through the year, there is a seasonally, our medical margin does drop down, and in Hawaii, in particular, that drives some pretty big deleverage, because it is a, you know, because it's a delegated model, we have a higher cost basis there. And so in the Q3, you know, without any acceleration of medical margin, you would see, you know, a bigger and bigger drag on EBITDA as we move through. And your math is correct, you know, that the absolute drag of Hawaii in the quarter was about $12 million to the EBITDA line. Got it. So it's normal seasonality. The second one was, I just, you know, I'm kind of probably not the only one struggling a little bit with the negative PPD that keeps showing up, but the concept also that you've been building reserves. But net, net, how do we, how do we think about carrying... You know, end of the day, the PPD says the prior, you know, the prior years, you know, cohort medical margin wasn't as good as you originally thought. The boosting of reserves says, you know, this year, medical margin won't be as high. How do we think about carrying that in over the next couple of years? Like, how does this development reserve building impact, you know, how you're thinking about modeling, you know, the cohort medical margin development? Well, you know, I can start, Tim, and you can jump in. I mean, Gary, I think the thought process is we've been building this year to remove the issue for next year. And so this year we have the impact of the negative PPD in our results. We also have the impact of, you know, the build, which is there to try and put us in a position where we don't have it going forward for next year. So I think you step off with a very strong run rate across REACH and MA. I think we have a plan to not have PPD recurring, which we've had in the last couple of years, so that should really help as we do that. And then we have a really strong class coming in for 2024, that we just told you is larger than we had previously told you, and the performance of that class, we expect to be at the very high end of our typical margin range. And so all of those things, I think, as you look towards 2024, are real positives for us. And that, that's been our goal. Our goal has been to deliver on the EBITDA for this year and to try and take this issue around negative PPD off the table, and we've had the ability to do that because of the strong performance. Okay. Thank you, Gary. We will now take our next question from Jailendra Singh from Truist Securities. Jailendra, your line is now open. Please go ahead. Thank you, and thanks for taking my questions. One quick clarification, if you're willing to share, who was the buyer for Hawaii asset? Was it a related party? And then my main question is on the topic of utilization trends. Like, one of your peer partners, Humana, talked about recently about having higher MLR from their PPO book of business, which I believe is, like, almost more than half of your membership. Curious, what you are seeing in terms of utilization trends among PPO members versus HMO members? And one more kind of same topic, like, some payers have talked about offering flex cards and OTC benefits as they view this as an advantage next year. How have been your discussion with them about getting reimbursed for this pressure as you are effectively taking on for them? So that's three questions in one. I'll go to that. So the buyer is an experienced, California-based organization that's really strong in delegated model services, so really strong in claims, very strong in customer service, and we think they're a great match with MDX Hawaii. So that's the first point. In terms of our PPO experience, you know, we've talked about this before. We are probably the largest risk-based player in terms of PPO in the country. Our PPO business is just over 50% of our membership. It's also the fastest growing component, and our PPO business performance is in line with our HMO business, and I think the reason for that is the differences in our model. A large payer with a broad network versus our high touch PCP patient model, which has the ability to guide that, that patient on where they're gonna go for specialty care. At our Investor Day, we shared over 90% of specialty referrals come through that primary care physician, even in a PPO model. That is allowing us to really deliver cost-effective care, and so our PPO experience is very strong. And then just on the... I think your question is on the flex card side. Our conversations with folks is that on an aggregate basis, we're probably seeing a reduction in those year-over-year in terms of the total dollars across our population, that, that will be, will be out on those. Thank you. Thank you, Jailendra. Our next question comes from George Hill, from Deutsche Bank. George, your line is now open. Please go ahead. Yeah, good evening, guys, and thanks for taking the question. Mine was actually pretty similar to Jailendra's, that I wanted to ask at a higher level, that I know that kind of going into the back half of the year, we were looking at a lot of the Medicare Advantage MCOs to ratchet back on benefit design, given the kind of the poor rate environment for 2024, the changes to the risk model. But it looks like most of them preserved benefits despite kind of the tough rate environment. I was wondering if you, if you could, and you've kind of communicated that, you know, that the negative rate environment would flow through to their risk-bearing care providers. So, I guess maybe just walk us through, at a high level, how you guys are thinking about what looks like a preservation of benefits and what looks like a tougher revenue environment, and just kind of how you're thinking about that with respect to medical margin and EBITDA margin? Yeah. So I mean, George, I think our outlook on 2024 is strong for the reasons I talked about, strong run rate, strong class coming in for 2024, being able to manage that new risk adjustment model very well. I think our view on aggregate supplemental benefits is that there will be a net pullback on those for the markets that we're in. It's a market-by-market basis. We don't have a lot of D-SNPs in our markets, and so that's kind of the view, and so that would be neutral to a net tailwind, meaning the supplemental benefit experience from 2023 to 2024. But the big drivers are really the step off and the run rate, the strong class of 2024, and then just our ability to drive kind of medical margin maturation year over year. George, I'd add one thing. I think when you look at our geographic exposures relative to some of the companies you were referring to, we've got a very different geographic exposure and a very different patient population that we serve, and you know, that's what really drives our view that the changes that you talked about are very manageable for Agilon. Okay. I appreciate the call. Thank you. Thank you, George. Our next question comes from Whit Mayo from Leerink Partners. Whit, your line is now open, please go ahead. Yeah, I've got just two really quick ones. But Tim, you've talked about the investments you guys are making to fix these blind spots on trend. Is there any update or anything you can share that gives you confidence that you're seeing some of these gaps begin to be improved here? And I just wanna be clear, I'm a little confused here on the guidance here, but I think it was last quarter, you guided to a $30 million increase in the reserves within that Q3 range. And so are you saying there's another $30 million now on top of the previously contemplated $30 million? Sorry, I'm just. I think some of us are a little confused. Yeah. So maybe we can start with the guidance. I think last time we talked about a total of $60 million in Q3, and what we are saying is there's another $30 million in Q4. So that is the combination of those two. I think it's, and we're able to do that because of the strong overall performance across. In terms of the investments that we're making, I do think we're making progress with our payer partners on the data submission. I think it's, you know, it's really in terms of getting that information from there, where we're getting it in a faster way. But the other thing I would tell you is that our REACH real-time data tells us that we're tracking pretty well with that, and that we're able to manage things within kind of the ranges that we expected. Inpatient continues to be down, outpatient is up, but we will take that trade kind of all day long, and that's true across MA and across REACH. But those investments we made in the new data officer we brought in is making us better for that. And we are, you know, building reserves so that we make sure we're adequately reserved if development does come through. So can I ask just one final... I'm sorry, I'm confused on this point. So does the guidance, is it 60 total, or is it 90 now? Yeah, so when we came through the second quarter and said, "Hey, we're gonna basically increase our outlook for reserves," because we didn't feel like we had clear visibility to some of the increases in utilization that the big payers were putting out there. So now we've actually seen that. We did see that spike up in May, moderated a lot in June, came back down, continued to come down in July. So we've now accounted for that, and that was part of our, you know, increase on a rate basis of $60 million of medical expense that we had forecast or that we had guided through coming out of the second quarter. And we've accounted for that all now in the Q3 results that we just published. As we look forward now to the Q4, we've assumed that, you know, even though the spike in May clearly has moderated down some, that we're not gonna forecast that it's gonna moderate any further, or our guidance doesn't anticipate it's gonna moderate any further. And that would essentially represent an additional $30 million that we've put into our medical margin or medical expense forecast for the second half, and is the second reason why our medical margin forecast for MA has come down. So it's an additional $30 million, makes this assumption that we don't see any further moderation in claims and puts us, we believe, in a strong position to minimize the possibility that there'll be negative development bleeding through into 2023. And we're able to do that at the same time, you know, maintaining and actually slightly raising the midpoint of our overall EBITDA guidance for the year. Okay, thanks for the clarification. Thank you, Whit. We will now take our next question from Adam Ron, from Bank of America. Adam, your line is now open. Please go ahead. Hey, I have a quick one on cash flow. It seems like adjusted EBITDA is up $50 million year-to-date, year-over-year, but cash flow from operations is actually down. It looks like working capital use has, like, doubled year-over-year. Just wondering what's driving that, if it's a timing thing, if we should expect to step up in Q4, and just generally, how we should think about EBITDA flow through into cash flow. Thanks. Yeah, Adam, thanks for the question. I mean, it's always a timing thing with cash flow. Our cash flow, when you think about when our final payments and our big payments come in from payers, when years are settled up and our surplus is settled up, we typically do have a lag of, you know, when EBITDA is generated versus when we actually see the cash for that. So, the fact that we have a large number of new payers and a large number of new markets this year, I think something like 34% of our members are actually from this year or are on the MA side, are actually from new from our new markets. That just exacerbates that delay, essentially. So, we always say that the, you know, the EBITDA that we're generating this year, we would primarily see transitioning into improved cash flow in the next year or so. A little bit in the Q3, we also have, just with the sheer number of new payers and new markets we have, a little bit of a timing issue, even when we would normally get some of that settled up. And so we've got maybe a little bit less cash payments that came in in Q3 that'll come in through the rest of the year. But yeah, we always do have a, you know, a timing disconnect between the EBITDA we're generating and the cash that we receive for that performance. Thank you, Adam. Our next question comes from Jamie Perse from Goldman Sachs. Jamie, your line is now open. Please go ahead. Hey, thanks. Good afternoon. First, one quick clarification on the $60 million medical margin reduction, you know, year to date. How much of that is from changes in utilization patterns that you've seen, and how much of that is from, you know, insulation from future prior period development? And then my second question, just on new membership for next year, the 25,000 from ACO REACH and 110,000 from MA. You guys have previously said, you know, higher starting point on medical margin per member, per month next year. I think you've given above $60 for that on the MA side. How should we think about that in light of what you're seeing in utilization and the new reserving policies? Similar question on ACO REACH, just, you know, do you think the 300 basis point delta versus the benchmark can hold next year? Thank you. So maybe I'll take the second one first. It's easier. So I think that we think we're gonna be really strong with this class of 2024 next year and above that $60 PMPM range. And our implementation has gone extremely well around that. It's part of our investments in technology, it's part of a faster sales cycle, so there's a longer implementation period. So that's, you know, on the MA side. On the REACH side, we believe our performance is gonna carry forward for us. It's always in relation to sort of the net or the macro utilization across the entire Medicare book overall. But every year we've been positive relative to that, anywhere from 100 to 300+ basis points. So I think we would expect for all the reasons we talked about earlier, that that would continue for us on a go-forward basis. Yeah, and just to follow on, then back to the beginning of the question, just to follow on the REACH question. I mean, one of the things that we've talked about is, of course, REACH, the revenue benchmark, what we're gonna get paid, basically moderates within the year based on utilization. So, you know, as long as we continue to do a good job, which we have been doing, of outperforming the Medicare fee-for-service benchmark performance, then we'll continue to drive really good performance on REACH. And as I said, this year, we're outperforming that, that fee-for-service population with our, with our population by over 300 basis points. So, you know, our, our model is really having a very positive impact. You can really see the power of the model on that, was previously largely unmanaged population. In terms of the guidance that we put out for medical expense in the Q4, you know, we basically just to reiterate what I said before, looked at it and said, "Hey, let's kind of take a viewpoint that the spike up in May that moderated down somewhat in July or somewhat in June and July is not gonna moderate down further." And based on that, we're putting, you know, a full another $30 million into our medical expense forecast and therefore, you know, a medical margin forecast for the Q4. You know, we think that that, you know, puts us in a good position to meet one of our key objectives, which is, you know, let's be at appropriately reserved to not have any prior period development bleed over into 2024. You know, I don't really want to divide it into categories as much as to say we've looked at the expense trend and tried to be appropriately conservative, to try to, you know, make sure that we're preventing or at least minimizing the possibility of that happening again next year. Thank you, Jamie. We will now take our next question from Elizabeth Anderson, from Evercore ISI. Elizabeth, your line is now open. Please go ahead. Hi, guys. Thanks so much for the question this evening. One, I was hoping you could speak sort of qualitatively on... I know you've talked about how you're doing, like, additional reserving and, et cetera, to help sort of manage the utilization as we go into 2024. I think you also mentioned in your prepared remarks that you're also making some qualitative changes on that, and I was just, just wondering how you're sort of thinking about that in terms of the claim management. And then secondarily, I was just wondering if you could comment a little bit further on the change in trajectory of geographic entry costs, and how that has sort of trended versus your initial expectations, given the large size of the class. Thank you. So I think, Elizabeth, on your first one, Tim walked through the math on, you know, the reserves. I think maybe what you're speaking to is we have added a SVP of data solutions, and we are working much more closely with payer partners to make sure that we're getting data in a consistent and more ready fashion around that. So we're making progress on that. Do you wanna talk about geographic costs? Yeah, and I was just gonna say, to add to that, I wasn't quite... Sorry, Elizabeth, I wasn't quite sure what the premise of that first question, but if it's along those lines. The other thing I would say is on prior period development is obviously we did have some key partner market prior period development in this quarter that we just reported. But the good news is, I think we have made a lot of progress across our broad payer platform with improving the quality and the timeliness of information we're getting from them. And, you know, if there's a silver lining in this quarter, it was really a very specific limited issue with one payer. So, you know, hopefully the investments we're making there, the investments and more expertise that we brought in is gonna really pay some dividends going forward. So we're feeling, we're feeling better about that. On geographic entry costs, we were a little bit better in the quarter than what we had forecast. You know, we're trying to make sure that we're, you know, since that's a new way that we're essentially reporting our adjusted EBITDA this year, that we're a little bit conservative in that number, but, we were a little bit better. But I think, you know, overall, going forward, our all-in geographic entry costs, we still expect to be in the, you know, $400-$600 range per new member that we're implementing for the next year. So I don't think we're going to see a lot of movement, and, you know, we'll probably continue to stay within that range. Thanks so much. Thank you, Elizabeth. Our next question comes from Sean Dodge, from RBC Capital Markets. Sean, your line is now open. Please go ahead. Hey, good afternoon. This is Thomas Keller on for Sean. Thanks for taking the question. Just one on the higher acuity clinical programs you all have. Were these capabilities already fully implemented across your the older cohorts, 2018, 2019, I guess during 2022? And so I guess what I'm looking to understand is kind of your latest thoughts on the upside from the rollout of these capabilities for those cohorts that are already generating medical margin PMPMs kind of north of 200. Thanks. Yeah. Thanks for the question. I mean, I think, you know, one of the distinctive parts of our model is that we've got these programs around renal, around palliative, around high-risk management, that are part of the care team around that PCP. We get much better enrollment rates and much better impact. That's how we're able to drive things like negative inpatient trends. To date, we're about, you know, 60% implemented across all of our markets. Our earliest markets do have those rolled out. By the end of 2024, we will have them across all markets, including the 24 markets. So I think we do believe that there's upside from these clinical programs as we get them more fully rolled out. Okay, thanks. Appreciate the time. Thank you, Sean. Our next question is from Jack Wallace, from Guggenheim. Jack, your line is now open. Please go ahead. Hey, thanks for taking my question. Just wanted to follow up to the cash flow question from earlier, and just given the moving pieces this year to help Hawaii, larger than normal, new class for next year, so the incremental reserves, do you think that it's, you know, reasonable to expect the, the, you know, free cash flow positive next year, or is that maybe more realistic for the 2025 timeline? Yeah, we're still. And, you know, one of the things I said before is we had a very big class come in this year. Actually, that class is performing really well. I think that 2020 class of 2024 is gonna be even a stronger performing class, but we're really pleased with the large class we brought in this year and where they're performing. As all of the incremental EBITDA that we're generating this year kind of flows into next year, that's gonna be a big supporter of our ability to generate positive free cash flow this year. So for now, we're still on track to do that. Obviously, we'll keep you updated as things move through next year, but at this point, we're still feeling pretty good about next year being kind of a transition year into positive free cash flow. Excellent. That's all for me. Thank you. Thank you, Jack. We have no time for further questions. With that, I will hand back to Steve Sell, CEO, for final remarks. Thank you, everyone. We appreciate your interest in our company, and we look forward to updating you on future calls. We will talk to you soon. This concludes today's call. Thank you all for your participation. You may now disconnect your lines.